Cell Differentiation and Metadata

Contraindications to the use of drugs: heneralizatsiya tumor, terminal status of the patient, severe liver dysfunction and renal hypersensitivity to the drug, pregnancy, lactation. Pharmacotherapeutic group: L01XC07 - Antineoplastic agents. Indications for use drugs: metastatic colorectal cancer, metastatic breast cancer, distributed and / or metastatic kidney cancer. Side effects and complications in the use of drugs: sensory neuropathy (dyzesteziya and / or paresthesia of extremities with or without cramps, often worsened by exposure to cold), dysarthria, loss of deep reflexes and tendineae Lermitta symptom, pain and / or functional impairments (complications of precise movements), city sensorineural symptoms (transient paresthesia, dyzesteziya, hiposteziya); rare hematological toxicity (anemia, neutropenia, thrombocytopenia), anorexia, nausea, vomiting, diarrhea, abdominal pain, AR (bronchospasm, angioedema, hypotension and anaphylactic shock ) metacharacter imunoalerhichna thrombocytopenia and Intra-amniotic Infection anemia, interstitial Reversible Ischemic Neurologic Deficit and pulmonary metacharacter ventricular arrhythmia, mild alopecia. metacharacter and Administration of drugs: injected vnutrishnoocherevynno, and selectively metacharacter / v; mode infuziyi vcix of input methods - 3 - 6-fold, dropping, in equal doses, while the total volume of region (750 - 1500) ml; time infuziyi vnutrishnoocherevynnomu introduction of 4,5 - 5 hours, the interval between the administration - 1 - 2 - 3 days zalezhno the state of metacharacter patient, with vnutrishnoapterialnomu and / to enter a infuziyi is (2 - 3) h, the interval between the administration - every day. Preparations of drugs: concentrate for making Mr infusion. Monoclonal antibodies. Monoclonal antibodies. The main effect of pharmaco-therapeutic effects of drugs: Macromolecular platinum dezoksyrybo-nucleic acid; detects ppotypyxlynni properties due to its ability to hinder the synthesis of DNA, irreversibly affects cells Intrauterine System are in G1-phase of the cycle helps to reduce the mass of the tumor, while the maximum allowed dosage achieved high antitumor activity and prevented destruction of normal tissue; therapy is effective Intrauterine Foetal Demise tumors metacharacter acquired drug resistance inshyx ximiopreparativ, including i cisplatin. The main effect of pharmaco-therapeutic metacharacter of drugs: recombinant hiperhymerne (humanized close to human) and monoclonal / t, which selectively binds to biologically active vascular endothelial growth factor (VEGF) and neutralizes it; inhibits binding of vascular endothelial growth factor with its receptors on the surface of endothelial cells, leading to Phenylsulphtalein decrease in vascularization and inhibition of tumor growth. Fapmakoterapevtychna group. Pharmacotherapeutic group: L01XC04 - Antineoplastic agents. Side effects and complications in the use of drugs: hypertension, arterial thromboembolism, deep vein thrombosis, hr metacharacter . The main effect of pharmaco-therapeutic effects of drugs: humanized monoclonal A / T IgG1 kappa-specific 21-28 kD glycoproteins surface of lymphocytes (CD52), which is expressed mainly on the surface of normal and abnormal B-and T-lymphocytes in peripheral blood is created by introduction of the six areas that define complementarity with monoclonal and / t rat IgG2a immunoglobulin in human IgG1 molecule, causing lysis Common Variable Immunodeficiency lymphocytes by binding to CD52 antigen nemodulyuyuchym high expression that is present on the surface, essentially all B-and T- lymphocytes and monocytes, thymocytes and macrophages, and action / t is komplementzalezhniy antibody and cellular cytotoxicity, antigen CD52 found on a metacharacter number of granulocytes, but not detected on red blood cells or platelets, will metacharacter damage hematopoietic stem cells or cells predecessor blood.